Welcome to our dedicated page for Unity Btech SEC filings (Ticker: UBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Unity Biotechnology, Inc.’s SEC filings for the historical Nasdaq symbol UBX and the over‑the‑counter symbol UNBX document both its clinical‑stage biotechnology activities and its transition toward dissolution. These filings are central for understanding how the company has described its senolytic and senescence‑modulating programs, its financial position, and the legal steps associated with delisting and winding down.
Through annual and quarterly reports on Form 10‑K and 10‑Q, Unity provides detailed discussions of its focus on therapeutics that selectively eliminate or modulate senescent cells to address age‑related ophthalmologic and neurologic diseases. These reports describe the development of UBX1325 for diabetic macular edema (DME), summarize the design and outcomes of the BEHOLD and ASPIRE clinical studies, and present research and development and general and administrative expenses. Investors can review these filings to see how Unity characterizes its clinical data, pipeline priorities, and cash resources over time.
Current reports on Form 8‑K are particularly important for Unity. A June 27, 2025 Form 8‑K explains Nasdaq’s determination that Unity no longer has an operating business and is a public shell, outlines the company’s notice of delisting, and describes the Board’s approval of a Plan of Dissolution under Delaware law. Subsequent 8‑K and 8‑K/A filings dated July 22 and July 24, 2025 detail the creation and issuance of a single Series A Preferred Share designed solely to vote on the dissolution proposal, as well as the mechanics of that security’s voting rights.
Listing and trading status changes are reflected in a Form 25 filed on August 6, 2025 by The Nasdaq Stock Market LLC, which formally removes Unity Biotechnology’s common stock from listing and registration under Section 12(b) of the Exchange Act. Earlier 8‑K filings describe the suspension of trading on Nasdaq on July 9, 2025 and the commencement of quotations on the OTC Pink Marketplace under the symbol UNBX.
Unity’s definitive proxy statement on Schedule 14A, filed August 11, 2025, is the primary source for information about the proposed liquidation and dissolution. It sets the agenda for a special meeting of stockholders to vote on the Dissolution Proposal and an Adjournment Proposal, outlines the Plan of Complete Liquidation and Dissolution, and discusses risk factors related to the dissolution process. The proxy statement notes that, based on information available at the time of filing, the company expected there would not be any amounts available for distribution to stockholders, while also explaining that the final outcome depends on resolving claims, obligations, and wind‑down expenses.
On Stock Titan’s filings page, users can access these Unity Biotechnology documents as they appear on EDGAR and use AI‑powered summaries to interpret complex sections. For example, AI tools can highlight key elements of Unity’s 10‑K and 10‑Q risk factors, extract the main terms of the Plan of Dissolution from the proxy statement, and clarify the implications of Forms 8‑K and 25 for shareholders. Filings related to insider or control‑person transactions, such as the issuance of the Series A Preferred Share, can also be examined to understand how voting control for the dissolution proposal is structured.
Together, Unity’s SEC filings provide a detailed regulatory record of its evolution from a clinical‑stage biotechnology issuer focused on senolytic ophthalmology programs to a public shell pursuing asset monetization, delisting from Nasdaq, and a planned corporate dissolution under Delaware law.
Unity Biotechnology, Inc. (UBX) is asking stockholders to approve a Plan of Complete Liquidation and Dissolution at a virtual Special Meeting on September 18, 2025 to authorize the Board to wind down the company. Only holders of record as of July 25, 2025 may vote; as of that date there were 17,212,172 shares of Common Stock outstanding and one share of Series A Preferred Stock that carries 600,000,000 votes and will vote in proportion to Common Stock votes on the Dissolution Proposal. The Board unanimously recommends a vote "FOR" the Dissolution and Adjournment proposals.
The Board approved the Dissolution and Plan of Dissolution on June 27, 2025, concurrently accepting the resignations of the CEO, CFO and CLO and reducing the Board from eight directors to one, appointing Craig R. Jalbert to lead the wind-down. The company ceased clinical development and expects to use remaining cash to pay winding-up costs first; based on information available at the time of this proxy statement, the Board expects there will not be any amounts available for distribution to stockholders. The company also disclosed its Common Stock was suspended from Nasdaq on July 9, 2025 and has been trading on the OTC Markets.
Unity Biotechnology, Inc. (UBX) filed a Form 25 indicating that the Nasdaq Stock Market LLC will remove UBX common stock from listing and registration under Section 12(b) of the Exchange Act. Nasdaq’s 2025-08-06 submission certifies compliance with Rule 12d2-2 requirements for delisting; the filing references both Exchange-initiated 12d2-2(b) and Issuer-initiated 12d2-2(c) pathways but does not specify which box is checked. No financial metrics, earnings data, or major transactions accompany the notice. Once effective (generally after 10 calendar days), UBX shares will no longer trade on Nasdaq, shifting to over-the-counter markets unless another listing venue is secured.